OncoSignal
Live from Open Targets Platform, fetched 2026-11-12 01:53 UTC. Every row links to its source record.

TCF7L2 transcription factor 7 like 2

ENSG00000148737 · protein coding · Open Targets profile

Participates in the Wnt signaling pathway and modulates MYC expression by binding to its promoter in a sequence-specific manner. Acts as a repressor in the absence of CTNNB1, and as activator in its presence. Activates transcription from promoters with several copies of the Tcf motif 5'-CCTTTGATC-3' in the presence of CTNNB1. TLE1, TLE2, TLE3 and TLE4 repress transactivation mediated by TCF7L2/TCF4 and CTNNB1. Expression of dominant-negative mutants results in cell-cycle arrest in G1. Necessary for the maintenance of the epithelial stem-cell compartment of the small intestine. {ECO:0000269|PubMed:12408868, ECO:0000269|PubMed:12727872, ECO:0000269|PubMed:19443654, ECO:0000269|PubMed:22699938, ECO:0000269|PubMed:9727977}.

In 10 of 15 cancers, the evidence for TCF7L2 comes mainly from mutations found in tumours

Each row is a cancer, strongest overall evidence first. The two dots show how strong the inherited (germline) and tumour-mutation (somatic) evidence is; the line between them is the gap.

Inherited (germline) variantsMutations in tumours (somatic)
00.250.50.751colorectal adenocarcinomacolorectal adenocarcinomacolorectal adenocarcinoma: somatic 0.75prostate carcinomaprostate carcinomaprostate carcinoma: somatic 0.46prostate carcinoma: germline 0.87breast carcinomabreast carcinomabreast carcinoma: somatic 0.46breast carcinoma: germline 0.78colon adenocarcinomacolon adenocarcinomacolon adenocarcinoma: somatic 0.68colorectal cancercolorectal cancercolorectal cancer: germline 0.65breast cancerbreast cancerbreast cancer: germline 0.76triple-negative breast carcinomatriple-negative breast carcinomatriple-negative breast carcinoma: germline 0.68esophageal adenocarcinomaesophageal adenocarcinomaesophageal adenocarcinoma: somatic 0.61carcinoma of liver and intrahepatic bil…carcinoma of liver and intrahepatic biliary tractcarcinoma of liver and intrahepatic biliary tract: somatic 0.61rectum adenocarcinomarectum adenocarcinomarectum adenocarcinoma: somatic 0.61hemangioblastomahemangioblastomahemangioblastoma: somatic 0.61kidney neoplasmkidney neoplasmkidney neoplasm: somatic 0.61skin basal cell carcinomaskin basal cell carcinomaskin basal cell carcinoma: somatic 0.61ovarian endometrioid adenocarcinoma wit…ovarian endometrioid adenocarcinoma with squamous differentiationovarian endometrioid adenocarcinoma with squamous differentiation: somatic 0.61hepatobiliary neoplasmhepatobiliary neoplasmhepatobiliary neoplasm: somatic 0.61

Scores run from 0 (no evidence) to 1 (strongest). A missing dot at 0 means Open Targets holds no evidence of that kind. Source: Open Targets Platform, fetched live.

Tractability

Small molecule
High-Quality Ligand
PROTAC
UniProt Ubiquitination, Database Ubiquitination, Small Molecule Binder

gnomAD loss of function constraint: o/e 0.29534000158309937 (upper bound 0.4184199869632721). Low values mean loss of function is poorly tolerated, a safety flag for inhibition.

Who runs trials of these drugs

No named investigators on registry trials of TCF7L2's approved or late-stage drugs in the last three years.

No terminated, withdrawn or suspended trials of TCF7L2's drugs are registered

All 0 drugs and clinical candidates as a table

Each drug, stage and indication links to its Open Targets record, where the trials and approvals behind it are listed. Salt forms (for example a mesylate) are listed as Open Targets records them, as separate entries.

DrugTypeHighest stageIndicationsSource records
No drugs or clinical candidates recorded.